Login to Your Account


Dual-action, dual-indication decoy fights tumors, viruses

By Anette Breindl
Senior Science Editor

Friday, January 13, 2017

Inhibiting the Axl kinase could have applications in both antitumor and antiviral therapy, separate papers published over the past few weeks have reported. In the Jan. 10, 2017, issue of Cell Reports, a team from the French INSERM Institute showed that Axl receptor activity both enabled Zika virus entry into cells and modulated innate immune responses.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription